What Should You Know Before Starting Spravato Treatment?
Reviewed by Nick Marino, Medical Director, Allay Health and Wellness
Most patients researching Spravato have already been through the cycle. Multiple antidepressants. Months of waiting to see if something works. Partial improvement that does not hold. Or no improvement at all. If that sounds familiar, you are likely in the right place to learn more. Starting Spravato treatment is a significant clinical decision. It involves a specific approval scope, a structured administration process, real side effects worth understanding, and eligibility criteria that not every patient will meet.
This guide covers what patients in Palm Beach Gardens and surrounding areas genuinely need to know before their first appointment. No vague reassurances. Clear, accurate information built on what the FDA has approved and what clinical care actually involves.
What Spravato Is Approved to Treat
This is the most important fact to understand before anything else. Spravato is an FDA-approved esketamine nasal spray. It carries approval for two specific indications only. The first is treatment-resistant depression in adults who have not responded adequately to at least two oral antidepressants used at adequate doses and for adequate durations. The second is depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior.
Spravato is not approved for PTSD, chronic pain, anxiety, OCD, or any other condition. Any provider who suggests otherwise is not following FDA guidelines. When considering starting Spravato treatment, confirming that your situation matches one of these two approved indications is a necessary first step.
Why REMS Certification Matters for Every Patient
Spravato is only available through a restricted distribution program called the Risk Evaluation and Mitigation Strategy, or REMS. This program exists because the medication can cause serious temporary side effects that require clinical supervision. Every clinic that administers Spravato must be certified under this program. Every patient must also be enrolled in REMS before receiving their first dose. This is not optional. It is a federal safety requirement embedded in every legitimate Spravato treatment program.
Before booking an appointment anywhere, confirm REMS certification directly with the clinic. A certified clinic will confirm this without hesitation. If a provider is vague about REMS enrollment, that is a meaningful red flag. Allay Health and Wellness is a REMS-certified Spravato provider. Learn more on our Spravato treatment page.
The Eligibility Evaluation You Need First
Starting Spravato treatment requires a thorough clinical evaluation before any session is scheduled. This is not a brief intake screening. It is a full assessment of your mental health history, prior treatment attempts, current medications, and overall medical health.
Providers use this evaluation to confirm that you meet the FDA-approved criteria for Spravato and that no contraindications are present. Not every patient with depression will qualify. Certain medical conditions, medication interactions, and clinical factors may affect eligibility. This step protects patients. It also gives providers the information they need to build a meaningful treatment plan rather than starting from assumptions. For a detailed breakdown of eligibility criteria, visit our page on Spravato criteria.
Side Effects That Require Clinical Monitoring
Every patient starting Spravato treatment deserves a clear and honest conversation about side effects before their first session. These are not rare edge cases. They are expected effects that occur frequently enough to require mandatory clinical oversight. The most common side effects include dissociation, sedation, nausea, dizziness, and temporary increases in blood pressure. Dissociation is particularly notable. Patients may feel detached from their surroundings, experience perceptual changes, or notice that time feels distorted during the session.
These effects are temporary. They typically peak within the first hour and reduce significantly before the monitoring period ends. Clinical staff are present throughout each session to support patients and respond to any unexpected reactions. Do not begin starting Spravato treatment with any provider who minimizes these effects or does not explain the monitoring protocol in advance.
What the Monitoring Period Involves
After each Spravato session, patients remain at the clinic for a mandatory observation period of at least two hours. This requirement is built into the REMS program and applies to every session, not just the first. The two-hour monitoring window is not downtime. It is active clinical supervision with a specific purpose. Understanding what takes place during this period helps patients prepare and reduces anxiety about the process.
- Blood pressure monitoring. Spravato can temporarily raise blood pressure. Staff measure and track this at defined intervals during the observation period. Any significant or persistent elevation is assessed by the clinical team before discharge is considered.
- Dissociation assessment. Clinical staff check in with patients at regular intervals during the observation period. They assess whether dissociative effects are resolving at the expected pace and document their observations as part of your clinical record.
- Nausea and comfort management. Some patients experience nausea following administration. The clinical environment is designed to support patient comfort, and staff address any symptoms that arise during the session or observation window.
- Discharge clearance. A licensed clinician reviews your status before you leave. They confirm that blood pressure has stabilized, that dissociative effects have resolved to a safe level, and that you are ready for discharge. You will not be cleared to leave until this review is complete.
Why You Cannot Drive on Treatment Days
Patients starting Spravato treatment must arrange transportation for every session day. Driving on the day of a Spravato session is not permitted. This applies after every appointment, not just the first. Spravato causes sedation and dissociation that affect reaction time, coordination, and cognitive function. These effects may persist even after the monitoring period ends. Operating a vehicle in this state creates serious safety risks for the patient and others.
A responsible adult must be available to drive you home from each session. Plan this arrangement before your first appointment. Patients who cannot arrange transportation on a particular day should reschedule rather than attempt to drive. For more detail on this requirement, visit our page on driving after Spravato treatment.
How the Treatment Schedule Is Structured
Spravato treatment follows a structured schedule that changes over time. Understanding the general phases can help patients plan appointments and know what to expect. The schedule is based on the FDA-approved dosing regimen, but the exact treatment plan depends on your clinical situation and your provider’s assessment. Your provider will monitor your response and determine whether continuing, adjusting, or stopping treatment is appropriate. Here is how the treatment phases are generally structured:
Induction Phase
During the first four weeks, Spravato is typically administered twice a week. This initial phase allows your provider to monitor how you respond to treatment and assess whether the medication is appropriate for continued use. Each treatment takes place under required monitoring. Your provider will review your progress and determine the next steps based on your individual clinical response.
Stabilization Phase
After the first four weeks, Spravato is typically administered once a week for another four weeks. During this phase, your provider continues to monitor your response and overall clinical status. The goal is to evaluate how you are doing with the reduced treatment frequency. Your provider will use this information when determining whether the treatment schedule should continue or change.
Maintenance Phase
Following the stabilization phase, Spravato may be administered once every one or two weeks, depending on your clinical response. There is no single maintenance schedule that applies to every patient. Your licensed healthcare provider will assess your symptoms, treatment response, and overall situation before recommending an ongoing schedule.
Schedule Adjustments
Your Spravato schedule may change based on your individual clinical needs and response to treatment. Do not change the frequency or stop treatment on your own. If you notice changes in your symptoms, side effects, or other concerns between appointments, tell your provider. They can determine whether a schedule adjustment or further evaluation is appropriate.
For more information about scheduling, visit our page on Spravato treatment frequency.
What to Prepare Before Your First Session
Preparing for your first Spravato session can make the experience feel more organized and less stressful. Because Spravato treatment involves specific safety and monitoring requirements, it is important to follow your provider’s instructions before arriving. Planning ahead also helps you avoid last-minute problems with transportation, medications, or your schedule. Your clinic may provide additional instructions based on your individual health needs and treatment plan. Before your appointment, make sure you:
- Bring a written medication list including dosages, prescribing providers, and any supplements you take
- Follow pre-session food and drink instructions provided by your clinic, typically avoiding food for at least two hours beforehand
- Arrange transportation in advance so your driver is confirmed before your appointment day arrives
- Write down questions you want answered before the session begins so nothing important gets missed
- Clear your schedule for the remainder of the treatment day and plan for rest afterward
How Spravato Compares to IV Ketamine
Some patients evaluating starting Spravato treatment also want to understand how it compares to IV ketamine infusions. These are related but distinct options with different approval statuses and clinical structures. Spravato is FDA-approved for its specific indications. IV ketamine for depression is an off-label treatment, meaning it is not FDA-approved for this use. Both are administered in clinical settings with monitoring.
Coverage, cost, administration method, and eligibility differ between the two. A licensed provider can explain which option may be more clinically appropriate based on your individual history and diagnosis. For a side-by-side comparison, visit our page on Spravato vs. ketamine for depression.
Insurance and Coverage Considerations
Because Spravato is FDA-approved, it is more commonly covered by insurance than off-label treatments. However, coverage depends on your specific plan, your diagnosis, and whether prior authorization is required. Coverage may apply. Verify directly with your insurer before beginning treatment. Ask whether prior authorization is needed and what documentation your provider must submit. Our team assists with benefit verification and prior authorization support where possible.
Crisis Resources
If you are experiencing thoughts of self-harm or suicidal ideation, please contact the Suicide and Crisis Lifeline immediately by calling or texting 988. Starting Spravato treatment is a planned clinical process with evaluation and scheduling requirements. It is not emergency care and cannot replace immediate crisis support.
Begin the Process at Allay Health and Wellness
At Allay Health and Wellness, our licensed clinical team guides patients through every stage of starting Spravato treatment, from evaluation to ongoing monitoring and follow-up care. We serve patients in Palm Beach Gardens, West Palm Beach, and surrounding Palm Beach County communities. Coverage may apply. Verify with your insurer before your first appointment.
Address: 11000 Prosperity Farms Rd, Suite 101, Palm Beach Gardens, FL 33410
Email: [email protected]
Phone: (561) 421-6444
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Spravato is FDA-approved for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. IV ketamine for depression is an off-label use and is not FDA-approved for this indication. Treatment eligibility, outcomes, and side effects vary by individual and require evaluation by a licensed healthcare provider. No outcomes are guaranteed. If you are in crisis, call or text 988.
